Skip to main content
. 2017 Aug 20;2017:7941432. doi: 10.1155/2017/7941432

Table 2.

Main characteristics and outcomes of the patients.

Patients
(N)
Sex
Age
Symptoms
duration (months)
Symptoms Date of
diagnoses
Histologic
type (differentiation)/grading
Site(s) of disease IP
(PAPS)
mmHg
Treatment after surgery Time from surgery to CT (days) N cycles of CT Disease status Overall survival (months)
1 F
45
9 Dyspnea
Right cardiac failure
2010 IS (fibrosarcoma)
G2
Local
M+ (lung, kidney, nodes)
85 CT 10
months
NA PD 26
2 F
65
2 Pain
Cough
2011 IS (osteocondroid diff)
G2
Local
(bilateral)
45 CT 50 6 NED 55
3 M
32
9 Fever
Pain
Dyspnea
2012 IS (undiff)
G3
Local
(unilateral)
65 CT 22 6 PD 6
4 F
74
8 Dyspnea
Pain
2012 IS (fibrous histiocytoma diff)
G3
Local
(unilateral)
CT 48 6 PD 8
5 F
77
7 Dyspnea
Pain
Cough
Hemoptysis
2012 IS (mixofibrous diff)
G2
Local
M+ (lung)
>60 CT 69 2 PD 6
6 F
49
33 Dyspnea 2013 IS (leiomuscolar diff)
G2
Local
M+ (lung)
90 CT 42 5 NED 28
7 F
64
15 Dyspnea
Pain
Dysesthesia
2014 IS (undiff)
G3
Local
(bilateral)
45 CT/RT 30 4 NED 21
8 M
77
2 Dyspnea
Pain
2015 IS (undiff)
G3
Local
(bilateral)
100 CT/RT 25 4 PR 11
9 F
49
2 Heart failure 2015 IS (undiff)
G3
Local
(bilateral)
45 CT/RT 36 4 NED 10
10 M
84
4 Dyspnea
Pain
2015 IS (undiff)
G2
Local
(bilateral)
70 CT 44 4 PD 8
11 F
37
6 Dyspnea
Hemoptysis
2016 IS (osteosarcoma diff)
G3
Local
(bilateral)
CT 30 4 NED 4

IS: intimal sarcoma; M+: metastatic disease; CT: chemotherapy (adriamycin and ifosfamide); RT: radiotherapy; NA: not applicable; PD: progressive disease; NED: not evidence of disease; PR: partial response. Patient died. CT was given at disease progression. The patient who died perioperatively was excluded.